SG11202100467VA - Therapeutic protein selection in simulated in vivo conditions - Google Patents
Therapeutic protein selection in simulated in vivo conditionsInfo
- Publication number
- SG11202100467VA SG11202100467VA SG11202100467VA SG11202100467VA SG11202100467VA SG 11202100467V A SG11202100467V A SG 11202100467VA SG 11202100467V A SG11202100467V A SG 11202100467VA SG 11202100467V A SG11202100467V A SG 11202100467VA SG 11202100467V A SG11202100467V A SG 11202100467VA
- Authority
- SG
- Singapore
- Prior art keywords
- simulated
- therapeutic protein
- vivo conditions
- protein selection
- selection
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718307P | 2018-08-13 | 2018-08-13 | |
| US201962865446P | 2019-06-24 | 2019-06-24 | |
| PCT/US2019/046104 WO2020036845A1 (en) | 2018-08-13 | 2019-08-12 | Therapeutic protein selection in simulated in vivo conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100467VA true SG11202100467VA (en) | 2021-02-25 |
Family
ID=67851212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100467VA SG11202100467VA (en) | 2018-08-13 | 2019-08-12 | Therapeutic protein selection in simulated in vivo conditions |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200064353A1 (en) |
| EP (1) | EP3837546A1 (en) |
| JP (1) | JP2021534393A (en) |
| KR (1) | KR20210044810A (en) |
| CN (1) | CN112639471B (en) |
| AU (1) | AU2019321282A1 (en) |
| BR (1) | BR112021002432A2 (en) |
| CA (1) | CA3106997A1 (en) |
| IL (1) | IL280564A (en) |
| MX (1) | MX2021001777A (en) |
| SG (1) | SG11202100467VA (en) |
| WO (1) | WO2020036845A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001777A (en) * | 2018-08-13 | 2021-04-19 | Regeneron Pharma | Therapeutic protein selection in simulated in vivo conditions. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3532626A1 (en) * | 1985-09-12 | 1987-03-19 | Boehringer Mannheim Gmbh | METHOD FOR DETERMINING A PARTNER OF AN IMMUNE REACTION |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| SG106672A1 (en) | 2002-03-08 | 2004-10-29 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| US8022188B2 (en) * | 2006-04-24 | 2011-09-20 | Abbott Laboratories | Immunosuppressant binding antibodies and methods of obtaining and using same |
| JP2010127827A (en) * | 2008-11-28 | 2010-06-10 | Abbott Japan Co Ltd | Nonspecific interaction inhibitor, and its application to diagnostic measuring system |
| MX2011014008A (en) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format. |
| US20150105274A1 (en) * | 2012-02-10 | 2015-04-16 | Phylogica Limited | Methods for the Characterisation of Interaction Sites on Target Proteins |
| EP2822970A1 (en) * | 2012-03-08 | 2015-01-14 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| AU2013285422B2 (en) * | 2012-07-04 | 2017-04-27 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
| WO2014062856A1 (en) * | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| EP3028043A4 (en) * | 2013-07-30 | 2017-04-19 | Bio-rad Laboratories, Inc. | Multiplex blocker beads for immunoassays |
| EP3261665A1 (en) * | 2015-02-24 | 2018-01-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| WO2016164835A1 (en) | 2015-04-08 | 2016-10-13 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| US10947350B2 (en) * | 2015-09-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Functional, segregated, charged telodendrimers and nanocarriers and methods of making and using same |
| CA3026521A1 (en) * | 2016-06-27 | 2018-01-04 | President And Fellows Of Harvard College | Compounds useful to treat metabolic disorders |
| AU2017334698A1 (en) * | 2016-09-27 | 2019-03-21 | Oncxerna Therapeutics, Inc. | Methods for treating cancer with bavituximab based on levels of β2-glycoprotein 1, and assays therefor |
| MX2021001777A (en) * | 2018-08-13 | 2021-04-19 | Regeneron Pharma | Therapeutic protein selection in simulated in vivo conditions. |
-
2019
- 2019-08-12 MX MX2021001777A patent/MX2021001777A/en unknown
- 2019-08-12 EP EP19763124.5A patent/EP3837546A1/en active Pending
- 2019-08-12 AU AU2019321282A patent/AU2019321282A1/en active Pending
- 2019-08-12 CN CN201980052965.6A patent/CN112639471B/en active Active
- 2019-08-12 KR KR1020217007004A patent/KR20210044810A/en not_active Application Discontinuation
- 2019-08-12 BR BR112021002432-8A patent/BR112021002432A2/en unknown
- 2019-08-12 US US16/537,811 patent/US20200064353A1/en active Pending
- 2019-08-12 SG SG11202100467VA patent/SG11202100467VA/en unknown
- 2019-08-12 CA CA3106997A patent/CA3106997A1/en active Pending
- 2019-08-12 JP JP2021507663A patent/JP2021534393A/en active Pending
- 2019-08-12 WO PCT/US2019/046104 patent/WO2020036845A1/en unknown
-
2021
- 2021-02-01 IL IL280564A patent/IL280564A/en unknown
-
2022
- 2022-08-22 US US17/892,618 patent/US11879896B2/en active Active
-
2023
- 2023-12-01 US US18/526,139 patent/US20240094219A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112639471A (en) | 2021-04-09 |
| BR112021002432A2 (en) | 2021-05-04 |
| US20230066527A1 (en) | 2023-03-02 |
| US11879896B2 (en) | 2024-01-23 |
| AU2019321282A1 (en) | 2021-02-18 |
| IL280564A (en) | 2021-03-25 |
| US20200064353A1 (en) | 2020-02-27 |
| EP3837546A1 (en) | 2021-06-23 |
| US20240094219A1 (en) | 2024-03-21 |
| CA3106997A1 (en) | 2020-02-20 |
| MX2021001777A (en) | 2021-04-19 |
| CN112639471B (en) | 2024-04-09 |
| KR20210044810A (en) | 2021-04-23 |
| JP2021534393A (en) | 2021-12-09 |
| WO2020036845A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276464A (en) | Methods and compositions for therapeutic protein delivery | |
| GB201820166D0 (en) | Therapeutic agents | |
| IL282794A (en) | Therapeutic methods | |
| GB201820165D0 (en) | Therapeutic agents | |
| GB2561352B (en) | Animal models and therapeutic molecules | |
| GB201816442D0 (en) | Animal models and therapeutic molecules | |
| HK1258376A1 (en) | Bi-specific therapeutic proteins for tissue repair | |
| DK3737402T3 (en) | Modificeret protein | |
| SG11202011000SA (en) | Taste and flavor-modifier proteins | |
| GB201805816D0 (en) | Therapeutic agents | |
| ZA201907063B (en) | Insecticidal proteins and methods for their use | |
| ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| IL292502A (en) | Therapeutic methods using vadadustat | |
| ZA201902689B (en) | Therapeutic protein | |
| EP4041295A4 (en) | Multi-domain protein vaccine | |
| IL290675A (en) | Therapeutic fusion proteins | |
| IL272050B1 (en) | Synthetic proteins and therapeutic uses thereof | |
| EP3585798A4 (en) | In vivo protein n-acylation | |
| IL280564A (en) | Therapeutic protein selection in simulated in vivo conditions | |
| EP3378947C0 (en) | Use of ed-b protein in diagnosis of tissue hyperplasia | |
| GB201814040D0 (en) | Testing and therapy | |
| IL282671A (en) | Therapeutic methods and compositions | |
| GB201907647D0 (en) | Therapeutic methods | |
| GB201918688D0 (en) | Improved human verification | |
| GB201904341D0 (en) | Therapeutic methods |